De Lisle Partners’s UroGen Pharma URGN Stock Holding History

De Lisle Partners’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-81,510	Closed	-$902K	–	188
2025 Q1	$902K	Hold	81,510	–	–	0.15%	145
2024 Q4	$868K	Hold	81,510	–	–	0.13%	152
2024 Q3	$1.04M	Hold	81,510	–	–	0.17%	139
2024 Q2	$1.37M	Buy	81,510 +4,417	+6%	+$62.8K	0.3%	89
2024 Q1	$1.15M	Buy	+77,093	New	+$1.26M	0.27%	98

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

De Lisle Partners's URGN Position: Q2 2025 in Review

De Lisle Partners sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 81,510 shares — an estimated $902K sold.

De Lisle Partners first reported a position in URGN in Q1 2024 and held it in 5 quarters. The position peaked at $1.37M in Q2 2024. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

De Lisle Partners reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
De Lisle Partners sold 81,510 UroGen Pharma shares in Q2 2025, an estimated $902K.
De Lisle Partners first reported a position in UroGen Pharma in Q1 2024 and held it in 5 quarters.
De Lisle Partners's UroGen Pharma position peaked at $1.37M in Q2 2024.
150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on De Lisle Partners's 13F filing for Q2 2025, filed 13 Aug 2025.